ライフサイエンスコーパス: AMI

1 AMI was a secondary diagnosis in 58% of patients.

2 AMI was classified by physician review, using a validate

3 AMI-MS has the potential to provide significant improvem

4 We identified 24,584 and 97,068 AMI patients via the patient- and the cause-of-death reg

5 In 444,253 AMI-CS admissions, noncardiac single or multiorgan failu

6 ECMO was used in 0.5% and 0.3% AMI admissions complicated by cardiogenic shock and card

7 We identified 45 331 AMI hospitalizations between 2000 and 2014.

8 During follow-up, there were 37,441 AMI incident cases and 95,138 CHF incident cases.

9 A total 90 648 AMI-CS admissions <=55 years of age were included, of wh

10 Our cohorts included 152,808 AMI and 223,283 HF patients.

11 Of the 402 825 AMI-CS admissions, 16.8%, 22.5%, 39.3%, and 21.4% were a

12 30-day readmission among older adults after AMI.

13 without diabetes) underwent CMR 3 days after AMI.

14 Fatalities after AMI were related to a high incidence of multi-organ fail

15 covery of cardiac contractile function after AMI compared to control mice.

16 r adverse cardiovascular events (MACE) after AMI.

17 performance to a MACE within 12 months after AMI was evaluated by using Cox proportional hazards mode

18 al trends of readmission and mortality after AMI and HF in Ontario, Canada, where reducing hospital r

19 ission after AMI, and 30-day mortality after AMI) were evaluated by practice-level socioeconomic disa

20 Thirty day mortality rates after AMI were higher among patients at the most disadvantaged

21 As such, readmission after AMI has been a target of financial penalties through Med

22 l infarction [AMI], 30-day readmission after AMI, and 30-day mortality after AMI) were evaluated by p

23 ost-cardiac arrest patients with shock after AMI randomized in the Neuroprotect (Neuroprotective Goal

24 ost-cardiac arrest patients with shock after AMI, targeting MAP between 80/85 and 100 mm Hg with addi

25 All AMI risk-adjusted mortality rates also declined from 200

26 .06, 1.34) for noncardiovascular death among AMI patients.

27 any delay in readmission or mortality among AMI and HF patients.

28 An AMI readmissions reduction program that increases outpat

29 We started an AMI readmissions reduction program in November 2017.

30 xis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular e

31 e was to, therefore, develop and validate an AMI readmission risk model for older patients who consid

32 survival rates in dialysis patients with an AMI.

33 In a secondary analysis, AMI and stroke were analyzed separately.

34 2.51; 95% CI ranged from 1.02 to 6.19), and AMI, for both periodontitis diagnostic criteria.

35 he severity of the periodontal condition and AMI, suggesting a possible relationship among the levels

36 els of periodontitis severity (exposure) and AMI (outcome).

37 We applied AMI-MS to identify inhibitors of a human histone deacety

38 , including all-cause death, cardiac arrest, AMI, cardiogenic shock, sustained ventricular arrhythmia

39 ients with a confirmed diagnosis of arterial AMI.

40 e was 71% for the 214 patients with arterial AMI.

41 ower likelihood of receiving guideline-based AMI therapies.

42 needs among women may reduce these sex-based AMI disparities.

43 t baseline were more common in women in both AMI subgroups (cognitive impairment, NSTEMI: 20.6% versu

44 100% and 0% of probability to be affected by AMI.

45 Furthermore, pIC(50)s, as measured by AMI-MS, showed a good correlation with values generated

46 Participants were stratified by AMI subtype (ST-segment-elevation myocardial infarction

47 All consecutive AMI cases from 1996 to 2013 enrolled in the SWEDEHEART r

48 ch is slightly higher than the corresponding AMI(3) 3D perovskites.

49 tients with troponin levels above diagnostic AMI threshold increased in women and men by 24.3% versus

50 silon expressing platelets in discriminating AMI vs. non-AMI conditions.

51 in admissions with non-ST-segment elevation AMI-CS, nonwhite race, and higher baseline comorbidity.

52 Higher rates of ST-elevation AMI-CS were noted in the Midwest and West.

53 pitalization for heart failure and non-fatal AMI at 12-months in ST-segment elevation myocardial infa

54 included 1,462,168 young adults with a first AMI (mean age 50 +/- 7 years, 71.5% men, 58.3% white) of

55 vador, Bahia, Brazil, diagnosed with a first AMI event, and compared to 414 individuals without a dia

56 During a first AMI in young adults in whom preventive measures are more

57 lence rates of modifiable RFs during a first AMI, sex/race differences, and temporal trends in U.S. y

58 to 59 years of age hospitalized for a first AMI.

59 after undergoing reperfusion for their first AMI.

60 ive method for quantifying the AAR following AMI, which unlike T2-mapping, is not affected by IPC.

61 use of cardioprotective therapies following AMI, focusing on the rational combination of judiciously

62 For AMI, risk-adjusted 30-day readmission rates declined fro

63 re for all 3 conditions (16.6% vs. 17.1% for AMI, 21.4% vs. 21.7% for CHF, and 16.3% vs. 16.4% for pn

64 s for heart failure, 581 (28.3%) of 2055 for AMI, and 724 (24.9%) of 2911 for pneumonia would change

65 dex admissions appearing in HEDIS, 14.4% for AMI, 18.4% for CHF, and 13.9% for pneumonia resulted in

66 % to 22.9%) and 7.8% (IQR: 6.5% to 9.4%) for AMI, 23.0% (IQR: 20.6% to 25.3%) and 11.4% (IQR: 10.2% t

67 re 24.6% and 8.4% for HF, 19.3% and 7.6% for AMI, and 18.3% and 8.5% for pneumonia.

68 Of these, 18.9% for AMI, 23.7% for CHF, and 18.3% for pneumonia resulted in

69 The AAPC for AMI in men was stable over the study period (-4.7% [95%

70 The AAPC for AMI in women was -4.6% (95% CI, -4.1 to -5.2) between 20

71 ion for chest pain or hospital admission for AMI between practices.

72 Among admissions for AMI, CHF, and pneumonia identified in MedPAR, 29.2%, 38.

73 when choosing a percutaneous MCS device for AMI-VSD.

74 ited States for AMI, but diverge for HF. For AMI and HF, admissions, readmissions, and mortality rate

75 ns at the Massachusetts General Hospital for AMI.

76 st-discharge following a hospitalization for AMI and HF-the 2 target cardiovascular conditions-as wel

77 The first hospitalization for AMI overall, and for ST-segment-elevation MI and non-ST-

78 o 2014, 28 732 weighted hospitalizations for AMI were sampled among patients aged 35 to 74 years.

79 older patients (44% women) hospitalized for AMI.

80 ous mechanical circulatory support (MCS) for AMI-VSD is unknown.

81 es than patients in traditional Medicare for AMI (17.2% vs. 16.9%; difference, 0.3 percentage point [

82 Among patients undergoing PCI for AMI complicated by cardiogenic shock from 2015 to 2017,

83 Among 28 304 patients undergoing PCI for AMI complicated by cardiogenic shock, the mean (SD) age

84 challenges in providing recommendations for AMI care in the COVID-19 era.

85 ysteine were associated with higher risk for AMI; whereas angiotensin-II-antagonists, calcium-channel

86 noise was associated with elevated risks for AMI and CHF incidence.

87 The RRs were similar for AMI (RR 1.67, 95% CI 1.00, 2.76) and stroke (RR 1.59, 95

88 io are consistent with the United States for AMI, but diverge for HF. For AMI and HF, admissions, rea

89 and December 31, 2017, receiving defect-free AMI care including guideline-recommended pharmacotherapy

90 Injection of exosomes isolated from AMI mice into wild-type mice downregulates CXCR4 express

91 n is selectively expressed by platelets from AMI patients, accounting for increased platelet activati

92 ents originally randomized, 120 patients had AMI with shock.

93 d severe periodontitis, the chance of having AMI was approximately two to four times greater than amo

94 and rehabilitation services, and had higher AMI volume and percutaneous coronary intervention use du

95 We identified hospitalized AMI among members >=35 years of age in Kaiser Permanente

96 s suggest that the incidence of hospitalized AMI declined between 2000 and 2014; however, declines in

97 However, AMI diagnosis is reliable only at intermediate and later

98 However, AMIs have been implemented only in planned amputations a

99 onsible for this antibody-mediated immunity (AMI) to Y. pestis remain poorly understood.

100 In AMI admissions, a steady increase was noted in the utili

101 In conclusion, in AMI managed with revascularization, both BB and ACEI/ARB

102 between 2000 and 2014; however, declines in AMI have slowed among women in comparison with men in re

103 tionally, we estimated that the decreases in AMI and HF incidence associated with residential greenne

104 e in the prevalence of multiorgan failure in AMI-CS.

105 le and multiple noncardiac organ failures in AMI-CS.

106 percutaneous MCS normalized hemodynamics in AMI-VSD, pulmonary capillary wedge pressure and shunting

107 In-hospital mortality remained high in AMI admissions treated with ECMO.

108 inhibits neutrophil-platelet interactions in AMI patients by targeting neutrophils.

109 ew light on the importance of neutrophils in AMI to Y. pestis and may provide a new correlate of prot

110 ella provides the optimal form of support in AMI-VSD.

111 95% confidence intervals (CIs) for incident AMI and CHF in relation to LAeq24 and LAeqNight using ra

112 tem, we examined temporal trends in incident AMI among women and men.

113 interval (CI): 4%, 9%] decrease in incident AMI and a 6% (95% CI: 4%, 7%) decrease in incident HF.

114 ssociated with an increased risk of incident AMI (HR = 1.07; 95% CI: 1.06, 1.08) and CHF (HR = 1.07;

115 arly, LAeqNight was associated with incident AMI (HR = 1.07; 95% CI: 1.05, 1.08) and CHF (HR = 1.06;

116 648 deaths) or acute myocardial infarction (AMI) (3670 patients; median 7.0 y follow-up; 758 deaths)

117 events such as acute myocardial infarction (AMI) and congestive heart failure (CHF) is inconclusive,

118 s of developing acute myocardial infarction (AMI) and dying from cardiovascular causes in comparison

119 ion rates after acute myocardial infarction (AMI) and heart failure (HF) hospitalizations have decrea

120 he incidence of acute myocardial infarction (AMI) and heart failure (HF), post-AMI and HF hospital re

121 eadmissions for acute myocardial infarction (AMI) and heart failure (HF).

122 complication of acute myocardial infarction (AMI) and is often associated with cardiogenic shock.

123 ospitalized for acute myocardial infarction (AMI) are costly and difficult to predict.

124 nd prognosis of acute myocardial infarction (AMI) are presented.

125 n patients with acute myocardial infarction (AMI) as a hospital-level performance metric and to evalu

126 rt-term risk of acute myocardial infarction (AMI) associated with drugs prescribed in Norway or Swede

127 rily focused on acute myocardial infarction (AMI) complicated by cardiogenic shock (AMICS).

128 t, mortality in acute myocardial infarction (AMI) complicated by cardiogenic shock (CS) remains high.

129 Acute myocardial infarction (AMI) complicated by cardiogenic shock is associated with

130 atients with an acute myocardial infarction (AMI) during the COVID-19 pandemic.

131 ical setting of acute myocardial infarction (AMI) for patient benefit has been disappointing.

132 s with possible acute myocardial infarction (AMI) has been shown to effectively identify a substantia

133 mortality from acute myocardial infarction (AMI) has decreased, whereas the prevalence of AMI has in

134 admission after acute myocardial infarction (AMI) has the potential to both improve quality and reduc

135 sis who have an acute myocardial infarction (AMI) have an exceedingly poor prognosis, but it is unkno

136 tes of incident acute myocardial infarction (AMI) have declined in the United States, yet disparities

137 der adults with acute myocardial infarction (AMI) have higher prevalence of functional impairments, i

138 der adults with acute myocardial infarction (AMI) have yielded mixed results.

139 with suspected acute myocardial infarction (AMI) is an unmet clinical need.

140 e-in or -out of acute myocardial infarction (AMI) is mandatory to improve diagnostic outcome and cost

141 he diagnosis of acute myocardial infarction (AMI) is missed more frequently in young women than men,

142 ge diagnosis of acute myocardial infarction (AMI) or stroke using International Classification of Dis

143 However, in acute myocardial infarction (AMI) patients, higher admission LDL-C and TG levels have

144 performance in acute myocardial infarction (AMI) remains controversial.

145 ly detection of acute myocardial infarction (AMI) upon the onset of chest pain symptoms is crucial fo

146 s (ACEI/ARB) in acute myocardial infarction (AMI) were largely conducted prior to the widespread adop

147 r complication, acute myocardial infarction (AMI), are the leading causes of disability and death wor

148 re measures for acute myocardial infarction (AMI), little is known about performance on a composite m

149 specifically on acute myocardial infarction (AMI), remains unexplored.

150 ackground After acute myocardial infarction (AMI), reperfusion injury is associated with microvascula

151 ith shock after acute myocardial infarction (AMI), the optimal level of pharmacologic support is unkn

152 oung women with acute myocardial infarction (AMI), who represent an extreme phenotype.

153 s with a recent acute myocardial infarction (AMI).

154 with suspected acute myocardial infarction (AMI).

155 mical marker of acute myocardial infarction (AMI).

156 n patients with acute myocardial infarction (AMI).

157 presenting with acute myocardial infarction (AMI).

158 rculation after acute myocardial infarction (AMI).

159 nd prognosis of acute myocardial infarction (AMI).

160 dial injury and acute myocardial infarction (AMI).

161 e could trigger acute myocardial infarction (AMI).

162 n patients with acute myocardial infarction (AMI).

163 tcome following acute myocardial infarction (AMI).

164 asingly used in acute myocardial infarction (AMI); however, there are limited large-scale national da

165 ck complicating acute myocardial infarction (AMI-CS).

166 0.42 to 0.47]; acute myocardial infarction [AMI], 0.37 [CI, 0.35 to 0.40]; and pneumonia, 0.50 [CI,

167 table angina or acute myocardial infarction [AMI], 30-day readmission after AMI, and 30-day mortality

168 The agonist antagonist myoneural interface (AMI) is one such bi-directional neural communication mod

169 development of an acoustic mist ionization (AMI) interface capable of contactless nanoliter-scale "i

170 nostic factors of acute mesenteric ischemia (AMI) in ICU patients.

171 In ~9 million AMI admissions, ECMO was used in 2962 (<0.01%) and impla

172 sing platelets in discriminating AMI vs. non-AMI conditions.

173 primary endpoint was a composite of nonfatal AMI, unscheduled revascularization, stroke, all-cause de

174 Here, we demonstrate the application of AMI-MS by developing an HTS-compatible assay that measur

175 from 2000 to 2014, a retrospective cohort of AMI utilizing ECMO was identified.

176 A retrospective cohort of AMI-CS admissions aged 18 to 55 years, during 2000 to 20

177 The cohort was comprised of AMI or HF patients 65 years of age or older who had been

178 drugs dispensed 1-7 days before the date of AMI diagnosis with 15-21 days' time -window for all the

179 dentified adults with a primary diagnosis of AMI and concomitant CS admitted to the United States cen

180 ty, cTnI is widely used for the diagnosis of AMI diseases.

181 cians' ability to recognize the diagnosis of AMI in women.

182 The final diagnosis of AMI was independently adjudicated using all available cl

183 ed to 414 individuals without a diagnosis of AMI.

184 evices allow accurate and rapid diagnosis of AMI.

185 omarkers for the early and late diagnosis of AMI.

186 e examined the incidence and risk factors of AMI among young patients, or whether clinical management

187 , Canada, from 2001 to 2015 and were free of AMI (referred to as the AMI cohort) or CHF (the CHF coho

188 diovascular mortality in both adults free of AMI and HF and the entire adult population.

189 oved cardiovascular health in people free of AMI and HF but not among individuals who have already de

190 the entire adult population, adults free of AMI and HF, and survivors of AMI or HF from 2000 to 2014

191 tionships between noise and the incidence of AMI and CHF with no evidence of threshold values.

192 e to road traffic noise and the incidence of AMI and CHF.

193 The annual incidence of AMI hospitalizations increased for young women but decre

194 Similarly, incidence of AMI increased by 11.5% and 9.8%.

195 associated with an increase in incidence of AMI regardless of sex, but had no major impact on clinic

196 may represent a pathophysiological marker of AMI that could be utilized in combination with troponin-

197 about performance on a composite measure of AMI care that assesses the delivery of many components o

198 isparities in the management and outcomes of AMI-CS.

199 MI) has decreased, whereas the prevalence of AMI has increased markedly, particularly among patients

200 ice for the early diagnosis and prognosis of AMI.

201 The overall proportion of AMI admissions attributable to young patients steadily i

202 The proportion of AMI hospitalizations attributable to young patients incr

203 Age- and sex-standardized incidence rates of AMI declined from 322.4 (95% CI, 311.0-333.9) in 2000 to

204 er increase or decrease the apparent risk of AMI.

205 associated with a further increased risk of AMI.

206 non-invasively evaluating the early stage of AMI/R and necrosis in conjunction with reperfusion injur

207 This was a retrospective cohort study of AMI-CS using the National Inpatient Sample database from

208 ance study conducts hospital surveillance of AMI in 4 US communities (MD, MN, MS, and NC).

209 adults free of AMI and HF, and survivors of AMI or HF from 2000 to 2014.

210 We examined how symptoms of AMI combine as unique symptom phenotypes in individual p

211 ased approach to pharmacological triggers of AMI and other diseases with acute, identifiable onsets.

212 Response rates were independent from type of AMI presentation, age, or sex.

213 ach, we found that the effects of PM(2.5) on AMI incidence and cardiovascular mortality may be 10% to

214 d for fast screening to rule-in and rule-out AMI patients.

215 Recently, an MS platform (AMI-MS) was introduced that uses acoustically generated

216 nfarction (AMI) and heart failure (HF), post-AMI and HF hospital readmissions, and mortality.

217 A newly developed model for 6-month post-AMI mortality in older adults was well calibrated and ha

218 s PCI (OR 0.84 95%CI 0.83-0.86) and previous AMI (OR 0.65 95%CI 0.64-0.67) were inversely related wit

219 delivery of many components of high-quality AMI care.

220 l events in our elderly patients with recent AMI who were treated with 1.8 g n-3 PUFAs daily for 2 ye

221 mized risk assessment early after reperfused AMI with incremental prognostic value over and above tha

222 with acute myocardial ischemia-reperfusion (AMI/R) injury and myocardial necrosis, as well as its co

223 This paper validates the resulting AMI's physiology, revealing robust viability and mechani

224 ute myocardial infarction-cardiogenic shock (AMI-CS) in young adults.

225 infarction complicated by cardiogenic shock (AMI-CS), despite limited evidence for their effectivenes

226 ute myocardial infarction-cardiogenic shock (AMI-CS).

227 SILVER-AMI (Comprehensive Evaluation of Risk in Older Adults wi

228 ed data from participants enrolled in SILVER-AMI (Comprehensive Evaluation of Risk Factors in Older P

229 y validated cardiovascular model to simulate AMI-VSD with parameters adjusted to replicate average he

230 Age- and sex-standardized AMI hospitalization rates in Ontario declined 32% from 2

231 ter, prospective, randomized, Phase III STEM-AMI OUTCOME trial, 161 ST-segment-elevation myocardial i

232 The STEM-AMI OUTCOME CMR (Stem Cells Mobilization in Acute Myocar

233 ng to an emergency department with suspected AMI were enrolled in a prospective, multicenter diagnost

234 but in different time blocks; hence the term AMI cases and not patients is used.

235 One important reason might be that AMI is multifactorial, causing cardiomyocyte death via m

236 In mice, we find that AMI is accompanied by an increase in circulating levels

237 Preliminary human evidence suggests that AMIs have the capacity to provide high fidelity control

238 The AMI-MS assay identified 86% of hits previously identifie

239 The AMI/R and necrosis groups showed significantly higher ra

240 015 and were free of AMI (referred to as the AMI cohort) or CHF (the CHF cohort) at baseline.

241 We compare the AMI-MS readout with conventional platforms in single-sho

242 taneous coronary intervention use during the AMI hospitalization.

243 ving agonist-antagonist muscle dynamics, the AMI allows proprioceptive signals from mechanoreceptors

244 s a revision model for implementation of the AMI in patients who are undergoing traumatic amputation

245 grafts, indicating the incorporation of the AMI into physiological reflexive loops.

246 c + Ala and (13)C Bicar/tC than those of the AMI/R group.

247 ys (IQR, 2.1-8.5 days) for CS not related to AMI, and 5.8 days (IQR, 2.9-10.0 days) for mixed shock v

248 aged 70 to 82 years with recent (2-8 weeks) AMI.

249 diabetes among young patients admitted with AMI increased over time as well.

250 Dialysis cases admitted with AMI were treated more invasively and received more disch

251 sive Evaluation of Risk in Older Adults with AMI) is a prospective cohort study of 3006 patients of a

252 We found 48 drugs to be associated with AMI in both countries.

253 that PM(2.5) was positively associated with AMI incidence and cardiovascular mortality with all four

254 Overall, dialysis cases with AMI have an improved in-hospital and 1-year survival in

255 Of 289 699 cases with AMI, 1398 (0.5%) were on dialysis (73.6% hemodialysis; 2

256 ast 18 years, more patients on dialysis with AMI have been treated with evidence-based therapies.

257 75 years or older who were hospitalized with AMI and discharged alive.

258 patients of age >=75 years hospitalized with AMI at 94 US hospitals.

259 Among older adults hospitalized with AMI, women had a higher prevalence of age-related functi

260 older adults (>=75 years) hospitalized with AMI.

261 study of 3501 young adults hospitalized with AMI.

262 c parameters reported in the literature with AMI-VSD.

263 Results Thirty-four participants with AMI underwent MRI an average of 5 days +/- 1.9 (standard

264 ean arterial pressure (MAP) in patients with AMI and shock after cardiac arrest.

265 Thirty-day home time for patients with AMI can be assessed as a hospital-level performance metr

266 retrospective cohort study of patients with AMI complicated by cardiogenic shock undergoing PCI betw

267 The study included 984 612 patients with AMI hospitalization across 2379 hospitals between 2009 a

268 rovements in the proportion of patients with AMI receiving defect-free care overall and across sociod

269 discrimination between HDs and patients with AMI was assessed on the basis of electrochemical thresho

270 dministration of selatogrel in patients with AMI was safe and induced a profound, rapid, and dose-rel

271 Patients with AMI were randomized to a single subcutaneous dose of sel

272 ul tool for risk assessment in patients with AMI who undergo PCI.

273 A total of 309 patients with AMI who underwent cardiac magnetic resonance imaging (CM

274 A total of 15,073 patients with AMI who underwent inhospital coronary revascularization

275 Among patients with AMI who underwent PCI, high post-PCI NLR value was assoc

276 Over the study period among patients with AMI, an intravascular microaxial LVAD was used in 6.2% o

277 Data of patients with AMI-CS treated with the Impella device at European terti

278 this retrospective analysis of patients with AMI-CS, the use of an Impella device was not associated

279 IABP) and medical treatment in patients with AMI-CS.

280 e Impella device on outcome in patients with AMI-CS.

281 dministration of selatogrel in patients with AMI.

282 eeded to improve care of young patients with AMI.

283 oking cessation counseling for patients with AMI.

284 s were significantly higher in patients with AMI.

285 with young men, young women presenting with AMI had a lower likelihood of receiving guideline-based

286 ed to young men, young women presenting with AMI were more often black and had a greater comorbidity

287 19 are complex with patients presenting with AMI, myocarditis simulating an ST-elevation myocardial i

288 8 sham-operated control rats and 8 rats with AMI-induced necrosis.

289 8 sham-operated control rats and 8 rats with AMI/R injury, and 8 sham-operated control rats and 8 rat

290 er missed diagnosis rate in young women with AMI and may have important implications for teaching and

291 Young women with AMI had higher inflammatory levels compared with young m

292 Women with AMI had lower rates of obstructive coronary disease (NST

293 Compared with men, women with AMI-CS were more frequently of Black race, from a lower

294 enrolled 4062 patients aged >/=18 years with AMI between April 11, 2005, and December 31, 2008, from

295 ICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic cardiomyopathy, and 17% had a c

296 3) versus AMICS (8; IQR, 5-11) or CS without AMI (7; IQR, 5-11; each P<0.01).

297 d 39% (95% CI, 31%-48%) in AMICS, CS without AMI, and mixed shock, respectively.

298 for trend<0.0001) also increased among young AMI patients.

299 In young AMI-CS admissions, women are treated less aggressively a

300 ecovery: Role of Gender on Outcomes of Young AMI Patients) was a multicenter, observational cohort st